IGC Pharma (IGS1) Price & Analysis

Q: What was IGC Pharma’s price range in the past 12 months?

IGC Pharma lowest stock price was €0.23 and its highest was €0.53 in the past 12 months.

Q: What is IGC Pharma’s market cap?

IGC Pharma’s market cap is $25.61M.

Q: When is IGC Pharma’s upcoming earnings report date?

IGC Pharma’s upcoming earnings report date is Feb 18, 2026 which is in 72 days.

Q: How were IGC Pharma’s earnings last quarter?

IGC Pharma released its earnings results on Nov 17, 2025. The company reported -€0.017 earnings per share for the quarter, the consensus estimate of -€0.017 by €0.

Q: Is IGC Pharma overvalued?

According to Wall Street analysts IGC Pharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does IGC Pharma pay dividends?

IGC Pharma does not currently pay dividends.

Q: What is IGC Pharma’s EPS estimate?

IGC Pharma’s EPS estimate is -0.02.

Q: How many shares outstanding does IGC Pharma have?

IGC Pharma has 92,868,240 shares outstanding.

Q: What happened to IGC Pharma’s price movement after its last earnings report?

IGC Pharma reported an EPS of -€0.017 in its last earnings report, expectations of -€0.017. Following the earnings report the stock price went up 2.013%.

Q: Which hedge fund is a major shareholder of IGC Pharma?

Currently, no hedge funds are holding shares in DE:IGS1

Compare

6 Followers

IGS1 Stock Chart & Stats

€0.26

<€0.01(0.63%)

At close: Jan 08 4:00 PM EST

€0.26

<€0.01(0.63%)

Day’s Range― - ―

52-Week Range€0.23 - €0.53

Previous CloseN/A

Volume0.00

Average Volume (3M)1.02K

Market Cap

$25.61M

Enterprise Value€36.73M

Total Cash (Recent Filing)$1.10M

Total Debt (Recent Filing)$137.00K

Price to Earnings (P/E)―

Beta-0.11

Next Earnings

Feb 18, 2026

EPS Estimate

-0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding92,868,240

10 Day Avg. Volume936

30 Day Avg. Volume1,023

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)3.45

Price to Sales (P/S)17.16

P/FCF Ratio-4.13

Enterprise Value/Market Cap1.43

Enterprise Value/Revenue33.21

Enterprise Value/Gross Profit71.88

Enterprise Value/Ebitda-5.70

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsIGC reported positive interim results from its Phase 2 trial for IGC-AD1, showing a significant reduction in agitation compared to placebo in patients with Alzheimer's disease.

Growth OpportunitiesThe company's strategic expansion into the $75 billion wellness industry with the launch of the Holiby brand offers new growth opportunities.

Market PotentialThe large market potential for Alzheimer's treatments presents high rewards despite the risks, given the growing number of Americans affected by the disease.

Bears Say

Market RisksThe large market potential for Alzheimer's disease treatment, due to the absence of a known cure and a growing number of patients, presents high rewards for the risks involved.

IGC Pharma News

IGC Pharma announces publication of caregiver book on Alzheimer’s

IGC Pharma (IGC) announced the publication of “Caring for a Loved One with Alzheimer’s Disease: First Hand Experiences,”...

6d ago

IGC

IGC Pharma leverages MINT-AD to identify risk factors driving Alzheimer’s

IGC Pharma (IGC) announced advances in MINT-AD, the Multimodal Interpretable Transformer for Alzheimer’s. Leveraging data from the Health...

13d ago

IGC

IGC Pharma expects ‘continued strong momentum’ into 2H26

The company said,”IGC expects continued strong momentum heading into the second half of fiscal 2026, with key strategic...

21d ago

IGC

IGC Pharma reports Q2 EPS (2c) vs. (2c) last year

Reports Q2 revenue $191,000 vs. $412,000 last year. “This quarter reflects the disciplined execution of our dual strategy...

21d ago

IGC

Options Volatility and Implied Earnings Moves Today, November 17, 2025

Today, several major companies are expected to report earnings: H World Group (HTHT), Danaos (DAC), Gladstone Capital (GLAD),...

21d ago

DAC

IGC Pharma files to sell 978,235 shares of common stock for holders

06:09 EST IGC Pharma (IGC) files to sell 978,235 shares of common stock for holders Published first on...

21d ago

IGC

IGC Pharma granted U.S. patent covering IGC-AD1

IGC Pharma (IGC) announced that the United States Patent and Trademark Office has granted the company U.S. Patent...

25d ago

IGC

IGC Pharma Reports Progress Amid Financial Losses

Igc Pharma, Inc. ( ($IGC) ) has released its Q2 earnings. Here is a breakdown of the information...

21d ago

IGC

IGC Pharma Sells Vancouver Assets to Wellness Essentials

IGC Pharma ( ($IGC) ) just unveiled an announcement. IGC Pharma, Inc., through its subsidiary Holi Hemp LLC,...

24d ago

IGC

IGC Pharma expands AI-powered in-Silico drug discovery platform

IGC Pharma (IGC) announced an expansion of its AI-powered in-Silico drug discovery platform. The company is now integrating...

1M ago

IGC

IGC Pharma’s Promising Alzheimer’s Agitation Study: Key Insights for Investors

Igc Pharma, Inc. (($IGC)) announced an update on their ongoing clinical study. Study Overview: The clinical trial titled...

1M ago

IGC

IGC Pharma expands Phase 2 CALMA trial to University of South Florida

IGC Pharma (IGC) announced the expansion of its ongoing Phase 2 CALMA clinical trial evaluating investigational drug candidate...

2M ago

IGC

IGC Pharma announces in-vitro preclinical data for IGC-1C

IGC Pharma (IGC) announced in-vitro findings for IGC-1C, a low-molecular weight compound. The data are consistent with IGC-1C...

2M ago

IGC

IGC Pharma Subsidiary Signs Asset Sale Agreement

IGC Pharma ( ($IGC) ) has provided an announcement. On September 29, 2025, IGC Pharma‘s subsidiary, Holi Hemp...

2M ago

IGC

IGS1 FAQ

What was IGC Pharma’s price range in the past 12 months?

IGC Pharma lowest stock price was €0.23 and its highest was €0.53 in the past 12 months.

What is IGC Pharma’s market cap?

IGC Pharma’s market cap is $25.61M.

When is IGC Pharma’s upcoming earnings report date?

IGC Pharma’s upcoming earnings report date is Feb 18, 2026 which is in 72 days.

How were IGC Pharma’s earnings last quarter?

IGC Pharma released its earnings results on Nov 17, 2025. The company reported -€0.017 earnings per share for the quarter, the consensus estimate of -€0.017 by €0.

Is IGC Pharma overvalued?

According to Wall Street analysts IGC Pharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does IGC Pharma pay dividends?

IGC Pharma does not currently pay dividends.

What is IGC Pharma’s EPS estimate?

IGC Pharma’s EPS estimate is -0.02.

How many shares outstanding does IGC Pharma have?

IGC Pharma has 92,868,240 shares outstanding.

What happened to IGC Pharma’s price movement after its last earnings report?

IGC Pharma reported an EPS of -€0.017 in its last earnings report, expectations of -€0.017. Following the earnings report the stock price went up 2.013%.

Which hedge fund is a major shareholder of IGC Pharma?

Currently, no hedge funds are holding shares in DE:IGS1

Company Description

IGC Pharma

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.